Enstilar is a dual-action investigational aerosol foam containing calcipotriol, a vitamin D analog, and betamethasone dipropionate, a corticosteroid.
Enstilar is specifically indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
Enstilar is supplied as a foam for topical administration.
Submit your review
Adverse effects associated with the use of Enstilar may include, but are not limited to, the following:
application site irritation
application site pruritus
exacerabation of psoriasis
It should be applied to affected areas once daily for up to 4 weeks, and rubbed in gently. Discontinue use when control is achieved. No more than 60 g every 4 days should be used.